JP2022527705A - 融合タンパク質およびその使用 - Google Patents
融合タンパク質およびその使用 Download PDFInfo
- Publication number
- JP2022527705A JP2022527705A JP2021556959A JP2021556959A JP2022527705A JP 2022527705 A JP2022527705 A JP 2022527705A JP 2021556959 A JP2021556959 A JP 2021556959A JP 2021556959 A JP2021556959 A JP 2021556959A JP 2022527705 A JP2022527705 A JP 2022527705A
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- seq
- amino acid
- cancer
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 147
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 146
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 67
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 55
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 55
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 55
- 239000013598 vector Substances 0.000 claims abstract description 55
- 238000000034 method Methods 0.000 claims abstract description 41
- 239000000203 mixture Substances 0.000 claims abstract description 39
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 163
- 230000027455 binding Effects 0.000 claims description 124
- 238000009739 binding Methods 0.000 claims description 121
- 239000012634 fragment Substances 0.000 claims description 78
- 210000004027 cell Anatomy 0.000 claims description 65
- 239000000427 antigen Substances 0.000 claims description 56
- 108091007433 antigens Proteins 0.000 claims description 56
- 102000036639 antigens Human genes 0.000 claims description 56
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 52
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 50
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 48
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 claims description 44
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 claims description 44
- 238000006467 substitution reaction Methods 0.000 claims description 43
- 102220283728 rs1064794204 Human genes 0.000 claims description 39
- 102220093685 rs374006397 Human genes 0.000 claims description 32
- 125000000539 amino acid group Chemical group 0.000 claims description 28
- 102200153332 rs116840818 Human genes 0.000 claims description 26
- 102220580619 Porphobilinogen deaminase_K98R_mutation Human genes 0.000 claims description 23
- 102220577898 Tyrosine-protein phosphatase non-receptor type substrate 1_L96S_mutation Human genes 0.000 claims description 23
- 102220250763 rs147081785 Human genes 0.000 claims description 17
- 102220164353 rs375686155 Human genes 0.000 claims description 17
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 16
- 230000003993 interaction Effects 0.000 claims description 16
- 102220492708 Protein phosphatase 1 regulatory subunit 7_E77Q_mutation Human genes 0.000 claims description 15
- 102220230344 rs1064794204 Human genes 0.000 claims description 15
- 102220070934 rs794728586 Human genes 0.000 claims description 15
- 102220483802 Aminopeptidase RNPEPL1_E84G_mutation Human genes 0.000 claims description 12
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 12
- 102220577895 Tyrosine-protein phosphatase non-receptor type substrate 1_D95E_mutation Human genes 0.000 claims description 12
- 230000000903 blocking effect Effects 0.000 claims description 12
- 102200078037 rs104895336 Human genes 0.000 claims description 12
- 210000004881 tumor cell Anatomy 0.000 claims description 12
- 102200118226 rs33959340 Human genes 0.000 claims description 11
- 102220070933 rs794728602 Human genes 0.000 claims description 11
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims description 9
- 102220481774 Kinesin-like protein KIF20A_I61F_mutation Human genes 0.000 claims description 9
- 102220384347 c.298A>G Human genes 0.000 claims description 9
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 7
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 7
- 208000032612 Glial tumor Diseases 0.000 claims description 7
- 206010018338 Glioma Diseases 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 7
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 7
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 7
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 7
- 201000010881 cervical cancer Diseases 0.000 claims description 7
- 201000004101 esophageal cancer Diseases 0.000 claims description 7
- 206010017758 gastric cancer Diseases 0.000 claims description 7
- 201000005202 lung cancer Diseases 0.000 claims description 7
- 208000020816 lung neoplasm Diseases 0.000 claims description 7
- 201000011549 stomach cancer Diseases 0.000 claims description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 102220577892 Tyrosine-protein phosphatase non-receptor type substrate 1_E77K_mutation Human genes 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims description 6
- 230000012010 growth Effects 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 230000035755 proliferation Effects 0.000 claims description 6
- 102220219557 rs1060501791 Human genes 0.000 claims description 6
- 102220188005 rs886053373 Human genes 0.000 claims description 6
- 238000007792 addition Methods 0.000 claims description 5
- 238000012217 deletion Methods 0.000 claims description 5
- 230000037430 deletion Effects 0.000 claims description 5
- 102000048776 human CD274 Human genes 0.000 claims description 5
- 206010005949 Bone cancer Diseases 0.000 claims description 4
- 208000018084 Bone neoplasm Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 4
- 208000017604 Hodgkin disease Diseases 0.000 claims description 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 4
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 4
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 4
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 4
- 206010057644 Testis cancer Diseases 0.000 claims description 4
- 210000002308 embryonic cell Anatomy 0.000 claims description 4
- 201000002313 intestinal cancer Diseases 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 210000002826 placenta Anatomy 0.000 claims description 4
- 206010038038 rectal cancer Diseases 0.000 claims description 4
- 201000001275 rectum cancer Diseases 0.000 claims description 4
- 102200047012 rs104894934 Human genes 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 201000003120 testicular cancer Diseases 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010067807 Gingival cancer Diseases 0.000 claims description 3
- 206010021042 Hypopharyngeal cancer Diseases 0.000 claims description 3
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 102220564808 Killer cell immunoglobulin-like receptor 2DL2_E77L_mutation Human genes 0.000 claims description 3
- 208000005450 Maxillary Sinus Neoplasms Diseases 0.000 claims description 3
- 102220488422 Olfactory receptor 10H4_N100K_mutation Human genes 0.000 claims description 3
- 102220488187 Olfactory receptor 2A12_I29L_mutation Human genes 0.000 claims description 3
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 3
- 206010034299 Penile cancer Diseases 0.000 claims description 3
- 102220582332 Porphobilinogen deaminase_R22C_mutation Human genes 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 206010062129 Tongue neoplasm Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000006593 Urologic Neoplasms Diseases 0.000 claims description 3
- 239000003708 ampul Substances 0.000 claims description 3
- 201000000053 blastoma Diseases 0.000 claims description 3
- 201000008184 embryoma Diseases 0.000 claims description 3
- 208000026043 eyelid cancer Diseases 0.000 claims description 3
- 201000006866 hypopharynx cancer Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 201000004488 maxillary sinus cancer Diseases 0.000 claims description 3
- 208000019303 maxillary sinus carcinoma Diseases 0.000 claims description 3
- 210000003101 oviduct Anatomy 0.000 claims description 3
- 230000002207 retinal effect Effects 0.000 claims description 3
- 102200113220 rs35220041 Human genes 0.000 claims description 3
- 201000006134 tongue cancer Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 239000008177 pharmaceutical agent Substances 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 11
- 208000023275 Autoimmune disease Diseases 0.000 abstract description 4
- 238000010586 diagram Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 53
- 108090000765 processed proteins & peptides Proteins 0.000 description 46
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 45
- 229920001184 polypeptide Polymers 0.000 description 44
- 102000004196 processed proteins & peptides Human genes 0.000 description 44
- 235000001014 amino acid Nutrition 0.000 description 40
- 102000004169 proteins and genes Human genes 0.000 description 36
- 235000018102 proteins Nutrition 0.000 description 31
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 19
- 150000001413 amino acids Chemical class 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 17
- 229940024606 amino acid Drugs 0.000 description 15
- -1 immune complexes Proteins 0.000 description 15
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 13
- 239000002773 nucleotide Substances 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 239000003814 drug Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 230000000259 anti-tumor effect Effects 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 241000283690 Bos taurus Species 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 6
- 241000283707 Capra Species 0.000 description 5
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 108020004511 Recombinant DNA Proteins 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 230000001605 fetal effect Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 4
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 231100000599 cytotoxic agent Toxicity 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 102100026882 Alpha-synuclein Human genes 0.000 description 3
- 108090001008 Avidin Proteins 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000001588 bifunctional effect Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 239000002619 cytotoxin Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 208000010932 epithelial neoplasm Diseases 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 208000014829 head and neck neoplasm Diseases 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000002751 lymph Anatomy 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 101100407306 Mus musculus Cd274 gene Proteins 0.000 description 2
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 208000000160 Olfactory Esthesioneuroblastoma Diseases 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 108010046722 Thrombospondin 1 Proteins 0.000 description 2
- 102100036034 Thrombospondin-1 Human genes 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 2
- 210000004507 artificial chromosome Anatomy 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000000536 complexating effect Effects 0.000 description 2
- 201000000787 conjunctival cancer Diseases 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 102000044459 human CD47 Human genes 0.000 description 2
- 102000048362 human PDCD1 Human genes 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 201000008859 olfactory neuroblastoma Diseases 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 235000002374 tyrosine Nutrition 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical group NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 101150084532 CD47 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- VPAXJOUATWLOPR-UHFFFAOYSA-N Conferone Chemical compound C1=CC(=O)OC2=CC(OCC3C4(C)CCC(=O)C(C)(C)C4CC=C3C)=CC=C21 VPAXJOUATWLOPR-UHFFFAOYSA-N 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101001066129 Homo sapiens Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000012270 PD-1 inhibitor Substances 0.000 description 1
- 239000012668 PD-1-inhibitor Substances 0.000 description 1
- 239000012271 PD-L1 inhibitor Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 101710094000 Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000019355 Synuclein Human genes 0.000 description 1
- 108050006783 Synuclein Proteins 0.000 description 1
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 108090000185 alpha-Synuclein Proteins 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- JECGPMYZUFFYJW-UHFFFAOYSA-N conferone Natural products CC1=CCC2C(C)(C)C(=O)CCC2(C)C1COc3cccc4C=CC(=O)Oc34 JECGPMYZUFFYJW-UHFFFAOYSA-N 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229950009791 durvalumab Drugs 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 239000010440 gypsum Substances 0.000 description 1
- 229910052602 gypsum Inorganic materials 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 102000047486 human GAPDH Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000028557 immunoglobulin binding proteins Human genes 0.000 description 1
- 108091009323 immunoglobulin binding proteins Proteins 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- SWKDMSRRIBZZAY-UHFFFAOYSA-N n-benzyl-n-(4,5-dihydro-1h-imidazol-2-ylmethyl)aniline;hydrochloride Chemical compound Cl.N=1CCNC=1CN(C=1C=CC=CC=1)CC1=CC=CC=C1 SWKDMSRRIBZZAY-UHFFFAOYSA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940121655 pd-1 inhibitor Drugs 0.000 description 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003017 phosphorus Chemical class 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 231100000336 radiotoxic Toxicity 0.000 description 1
- 230000001690 radiotoxic effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000563 toxic property Toxicity 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000002100 tumorsuppressive effect Effects 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
図2~3は、本発明に記載の融合タンパク質とPD-L1の結合能を示す。
図4は、本発明に記載の融合タンパク質とCD47の結合能を示す。
図5は、本発明に記載の融合タンパク質とPD-L1およびCD47の同時結合能を示す。
図6は、本発明に記載の融合タンパク質がCD47とそのリガンドSIRPαの結合を競合的に遮断することを示す。
図7~8は、本発明に記載の融合タンパク質がPD-1とPD-L1の結合を競合的に遮断することを示す。
図9~10は、本発明に記載の融合タンパク質を用いてマウス-ヒトリンパ腫の腫瘍モデルに腫瘍体積の増大を抑制することを示す。
一方、本発明は、第1結合ドメインと第2結合ドメインを含み得る融合タンパク質を提供する。上記の第1結合ドメインは、PD-L1に特異的に結合し、上記の第2結合ドメインは、CD47タンパク質に特異的に結合し、SEQ ID NO:29で表される配列に比べて、33位~149位における1つまたは複数(例えば、1~2つ、1~3つ、1~4つ、1~5つ、1~6つ、1~7つ、1~8つ、1~9つ、1~10つまたはより多く)の位置にアミノ酸残基の置換、欠失または付加を含むヒトSIRPα変異体1の突然変異体を含む。本発明に記載の融合タンパク質は、腫瘍関連抗原とCD47タンパク質に同時に特異的に結合することによって、腫瘍および/あるいは自己免疫疾患の治療に機能する。
本発明において、上記の突然変異体(例えば、CD47タンパク質に特異的に結合するヒトSIRPα変異体1の突然変異体)は、R22、I29、I61、V63、E77、Q82、K83、E84、V93、D95、L96、K98、N100、R107、G109およびV132からなる群から選ばれる1つまたは複数(例えば、1~2つ、1~3つ、1~4つ、1~5つ、1~6つ、1~7つ、1~8つ、1~9つ、1~10つまたはより多く)のアミノ酸残基にアミノ酸置換を含む。
本発明において、上記の第1結合ドメインは、抗体またはその抗原結合断片もしくは変異体を含み得る。例えば、上記の抗体は、モノクローナル抗体、一本鎖抗体、キメラ抗体、ヒト化抗体と完全ヒト化抗体からなる群から選ばれる。例えば、上記の抗原結合断片は、Fab、Fab'、(Fab')2、F(ab)2、dAb、散在している相補性決定領域CDR、FvおよびscFvからなる群から選ばれる。
本発明において、上記の第1結合ドメインは、上記の第2結合ドメインのN末端に位置してよい。例えば、上記の第1結合ドメインのC末端は、リンカーによって上記の第2結合ドメインのN末端に間接に連結してよい。いくつかの場合において、上記の第1結合ドメインのC末端は、第2結合ドメインのN末端に直接に(例えば、フレームワーク内)連結してもよい。
他方、本発明は、上記の融合タンパク質または上記の免疫複合体をコード化する1つまたは複数の単離された核酸分子を提供する。例えば、上記の1種または複数種の核酸分子における各核酸分子が、完全な上記の抗体またはその抗原結合断片をコード化することができるし、その一部(例えば、HCDR1-3、LCDR1-3、VL、VH、軽鎖あるいは重鎖のうちの1種または複数種)をコード化することもできる。
他方、本発明は、上記の融合タンパク質を含む免疫複合体を提供する。例えば、上記の免疫複合体は、本発明に記載の融合タンパク質が細胞毒性薬、放射性毒性薬剤(例えば、放射性同位体)および/または免疫阻害剤(例えば、免疫応答を抑制することなどによって細胞を殺傷するいかなる薬剤)などを含むが限定されない1種または複数種の治療薬と複合する融合タンパク質-薬物複合体(ADC)であってよい。いくつかの実施形態において、上記の治療薬は、腫瘍関連疾患または病症を治療可能な治療薬であってよい。
図1に示される融合タンパク質構造を参照して、ロシュPD-L1抗体Atezolizumab(SG1201)、SIRPα変異体1の突然変異体M91(SEQ ID:NO 41)を例として、N末端からC末端にかけて、選択的リンカー1(SEQ ID:NO 52)を選んで、順次にSG1201、リンカーとN末端がそれぞれSG1201の重鎖のC末端に連結した2つのM91に連結することによって、融合タンパク質SG12473が得られた。
(1)異なる抗原に対するヒト化抗体を対照とし、対応する二官能性タンパク質と関連抗原の結合活性に対してELISA評価を行った。
異なる抗原に対するヒト化抗体を対照とし、二重抗原に対する融合タンパク質SG12473および融合タンパク質SG12474による同時結合の生物学的活性に対してELISA分析を行った。
融合タンパク質SS002M91を対照とし、融合タンパク質SG12473、SG12474によるCD47/SIRPαの相互作用遮断の生物学的活性を評価した。
SG1201、SG1202を対照とし、融合タンパク質SG12473、SG12474によるPD-1/PD-L1の相互作用遮断の生物学的活性を評価した。
ヒトリンパ腫KARPAS-299細胞株を、雌NCGマウスMiXeno動物モデルに皮下で異種移植し、融合タンパク質SG12473の抗腫瘍活性効果を評価した。
群2Aと群2B:SG1201群、SG1201 5mg/Kg
群3Aと群3B:SG12473低用量群、SG12473 5mg/Kg
群4Aと群4B:SG12473中用量群、SG12473 10mg/Kg
群5Aと群5B:SG12473高用量群、SG12473 20mg/Kgであった。
本発明において、上記の突然変異体(例えば、CD47タンパク質に特異的に結合するヒトSIRPα変異体1の突然変異体)は、I61、V63、E77、Q82、K83、E84、V93、D95、L96、K98、N100、R107、G109およびV132からなる群から選ばれる1つまたは複数(例えば、1~2つ、1~3つ、1~4つ、1~5つ、1~6つ、1~7つ、1~8つ、1~9つ、1~10つまたはより多く)のアミノ酸残基にアミノ酸置換を含む。
Claims (41)
- PD-L1に特異的に結合する第1結合ドメイン、および
SEQ ID NO:29で表される配列に比べて、33位~149位における1つまたは複数の位置にアミノ酸残基の置換、欠失または付加を含むヒトSIRPα変異体1の突然変異体を含むCD47タンパク質に特異的に結合する第2結合ドメインを持つ、
融合タンパク質。 - 前記突然変異体は、R22、I29、I61、V63、E77、Q82、K83、E84、V93、D95、L96、K98、N100、R107、G109およびV132からなる群から選ばれる1つまたは複数のアミノ酸残基にアミノ酸置換を有する、
請求項1に記載の融合タンパク質。 - 前記突然変異体は、
(1)I61、V63、E77、E84、V93、L96、K98、N100およびV132、
(2)I61、E77、Q82、K83およびE84、
(3)I61、V63、K83、E84およびV132、
(4)I61、E77、E84、R107およびV132、
(5)I61、V63、E77、K83、E84およびN100、
(6)I6、E77、Q82、K83、E84およびR107、
(7)I61、E77、Q82、E84、V93、L96、N100、R107、G109およびV132、
(8)I61、E77、Q82、K83、E84およびV132、
(9)I61、
(10)I61、D95、L96、G109およびV132、
(11)I6、D95、L96、K98、G109およびV132、
(12)I61、E77、E84、V93、R107およびV132、
(13)E77、L96、N100、G109およびV132、
(14)I61、V63、Q82、E84、D95、L96、N100およびV132、
(15)I61、E77、Q82、K83、E84、V93、D95、L96、K98、N100およびV132、
(16)I61、E77、Q82、K83、E84およびV93、
(17)I61、V63、E77、K83、E84、D95、L96、K98およびN100、
(18)I61、V63、E77、K83、D95、L96、K98、N100およびG109、
(19)I61、E77、Q82、E84、V93、D95、L96、K98およびN100、ならびに、
(20)I61、V63、E77、Q82およびE84からなる群から選ばれるアミノ酸残基にアミノ酸置換を有する、
請求項2に記載の融合タンパク質。 - 前記突然変異体は、R22C、I29L、I61L/V/F、V63I、E77I/N/Q/K/H/M/R/N/V/L、Q82S/R/G/N、K83R、E84K/H/D/R/G、V93L/A、D95H/R/E、L96S/T、K98R、N100G/K/D/E、R107N/S、G109R/HおよびV132L/R/I/Sからなる群から選ばれる1つまたは複数のアミノ酸置換を有する、
請求項1~3のいずれか1項に記載の融合タンパク質。 - 前記突然変異体は、
(1)I61L、V63I、E77I、E84K、V93L、L96S、K98R、N100GおよびV132L、
(2)I61V、E77N、Q82S、K83RおよびE84H、
(3)I61F、V63I、K83R、E84KおよびV132I、
(4)I61L、E77Q、E84D、R107NおよびV132I、
(5)I61L、V63I、E77K、K83R、E84DおよびN100G、
(6)I61V、E77H、Q82R、K83R、E84HおよびR107S、
(7)I61L、E77I、Q82G、E84R、V93L、L96T、N100G、R107S、G109RおよびV132R、
(8)I61L、E77M、Q82G、K83R、E84DおよびV132L、
(9)I61L、
(10)I61F、D95H、L96S、G109HおよびV132S、
(11)I61F、D95H、L96S、K98R、G109HおよびV132S、
(12)I61L、E77Q、E84D、V93A、R107NおよびV132I、
(13)E77K、L96S、N100K、G109HおよびV132L、
(14)I61L、V63I、Q82G、E84G、D95R、L96S、N100DおよびV132I、
(15)I61L、E77R、Q82N、K83R、E84G、V93L、D95E、L96T、K98R、N100DおよびV132L、
(16)I61V、E77N、Q82S、K83R、E84HおよびV93A、
(17)I61V、V63I、E77V、K83R、E84D、D95E、L96T、K98RおよびN100E、
(18)I61L、V63I、E77V、K83R、D95E、L96S、K98R、N100DおよびG109R、
(19)I61V、E77L、Q82G、E84G、V93L、D95E、L96T、K98RおよびN100G、ならびに、
(20)I61L、V63I、E77N、Q82GおよびE84Gからなる群から選ばれるアミノ酸置換を有する、
請求項4に記載の融合タンパク質。 - 前記突然変異体は、SEQ ID NO:30-49のいずれかで表されるアミノ酸配列を有する、
請求項1~5のいずれか1項に記載の融合タンパク質。 - 前記第1結合ドメインは、抗体またはその抗原結合断片を含む、
請求項1~6のいずれか1項に記載の融合タンパク質。 - 前記抗体は、モノクローナル抗体、一本鎖抗体、キメラ抗体、ヒト化抗体および完全ヒト化抗体からなる群から選ばれる、
請求項7に記載の融合タンパク質。 - 前記抗原結合断片は、Fab、Fab’、F(ab)2、F(ab)2、dAb、散在している相補性決定領域CDR、FvおよびscFvからなる群から選ばれる、
請求項7~8のいずれか1項に記載の融合タンパク質。 - 前記PD-L1は、ヒトPD-L1である、
請求項1~9のいずれか1項に記載の融合タンパク質。 - 前記抗体は、SEQ ID NO:4、およびSEQ ID NO:18からなる群のうちのいずれか1つで表されるアミノ酸配列を有するHCDR1-3を含有する抗体重鎖またはその断片を含む、
請求項7~10のいずれか1項に記載の融合タンパク質。 - 前記HCDR2は、SEQ ID NO:5およびSEQ ID NO:19からなる群のうちのいずれか1つで表されるアミノ酸配列を有する、
請求項11に記載の融合タンパク質。 - 前記HCDR3は、SEQ ID NO:6およびSEQ ID NO:20からなる群のうちのいずれか1つで表されるアミノ酸配列を有する、
請求項11~12のいずれか1項に記載の融合タンパク質。 - 前記抗体重鎖またはその断片は、SEQ ID NO:8およびSEQ ID NO:22からなる群のうちのいずれか1つで表されるアミノ酸配列を有する重鎖可変領域VHを含む、
請求項11~13のいずれか1項に記載の融合タンパク質。 - 前記抗体重鎖またはその断片は、IgGを有する重鎖定常領域を含む、
請求項11~14のいずれか1項に記載の融合タンパク質。 - 前記IgGは、IgG1およびIgG4からなる群から選ばれる、
請求項15に記載の融合タンパク質。 - 前記抗体重鎖は、SEQ ID NO:13およびSEQ ID NO:27からなる群のうちのいずれか1つで表されるアミノ酸配列を有する、
請求項11~16のいずれか1項に記載の融合タンパク質。 - 前記抗体は、SEQ ID NO:1およびSEQ ID NO:15からなる群のうちのいずれか1つで表されるアミノ酸配列を有するLCDR1-3を含有する抗体軽鎖またはその断片を含む、
請求項6~17のいずれか1項に記載の融合タンパク質。 - 前記LCDR2は、SEQ ID NO:2およびSEQ ID NO:16からなる群のうちのいずれか1つで表されるアミノ酸配列を有する、
請求項18に記載の融合タンパク質。 - 前記LCDR3は、SEQ ID NO:3およびSEQ ID NO:17からなる群のうちのいずれか1つで表されるアミノ酸配列を有する、
請求項18~19のいずれか1項に記載の融合タンパク質。 - 前記抗体軽鎖またはその断片は、SEQ ID NO:7およびSEQ ID NO:21からなる群のうちのいずれか1つで表されるアミノ酸配列を有する軽鎖可変領域VLを含む、
請求項18~20のいずれか1項に記載の融合タンパク質。 - 前記抗体軽鎖またはその断片は、Igκを有する軽鎖定常領域を含む、
請求項18~21のいずれか1項に記載の融合タンパク質。 - 前記抗体軽鎖は、SEQ ID NO:11およびSEQ ID NO:25からなる群のうちのいずれか1つで表されるアミノ酸配列を有する、
請求項18~22のいずれか1項に記載の融合タンパク質。 - 前記第1結合ドメインは、前記第2結合ドメインのN末端に位置する、
請求項1~23のいずれか1項に記載の融合タンパク質。 - さらに、前記第1結合ドメインのC末端かつ前記第2結合ドメインのN末端にあるリンカーを有する、
請求項1~24のいずれか1項に記載の融合タンパク質。 - 前記リンカーは、SEQ ID NO:52で表されるアミノ酸配列を有する、
請求項25に記載の融合タンパク質。 - 少なくとも2つの前記第2結合ドメインを持つ、
請求項1~26のいずれか1項に記載の融合タンパク質。 - 各前記第2結合ドメインは、それぞれ前記第1結合ドメインのC末端に位置する、
請求項27に記載の融合タンパク質。 - 請求項1~28のいずれか1項に記載の融合タンパク質を含む、
免疫複合体。 - 請求項1~28のいずれか1項に記載の融合タンパク質または請求項29に記載の免疫複合体をコード化する、
1つまたは複数の単離された核酸分子。 - 請求項30に記載の核酸分子を含む、
1つまたは複数のベクター。 - 請求項1~28のいずれか1項に記載の融合タンパク質、請求項30に記載の免疫複合体、または請求項30に記載の核酸分子、および任意選択で薬学的に許容可能な賦形剤を含む、
組成物。 - 請求項1~28のいずれか1項に記載の融合タンパク質、請求項29に記載の免疫複合体、請求項30に記載の核酸分子、または請求項31に記載のベクターを含む、
細胞。 - 前記融合タンパク質を発現可能な条件で請求項33に記載の細胞を培養することを含む、
請求項1~28のいずれか1項に記載の融合タンパク質の調製方法。 - 腫瘍の治療のための医薬品の調製における請求項1~28のいずれか1項に記載の融合タンパク質、請求項29に記載の免疫複合体、請求項30に記載の核酸分子、請求項31に記載のベクター、請求項32に記載の組成物、または請求項33に記載の細胞の使用。
- 前記腫瘍は、固形腫瘍および非固形腫瘍を含む、
請求項35に記載の使用。 - 前記固形腫瘍および非固形腫瘍は、多発性骨髄腫、白血病、非ホジキンリンパ腫、ホジキンリンパ腫、神経膠腫、胚細胞腫瘍、肉腫、中皮腫、胎盤腫、脳癌、骨癌、皮膚がん、鼻咽頭癌、肺癌、口腔がん、食道がん、胃癌、肝臓がん、膵臓癌、前立腺がん、腸癌、乳がん、子宮頚部癌、卵巣癌および精巣癌、上顎洞癌、下咽頭がん、嗅神経芽細胞腫、舌癌、歯肉癌、膨大部癌、結腸がん、結直腸癌、腎臓癌、尿管癌、膀胱がん、陰茎癌、卵管癌、眼瞼癌、網膜芽細胞腫を含む、
請求項36に記載の使用。 - 腫瘍を治療するための請求項1~28のいずれか1項に記載の融合タンパク質、請求項29に記載の免疫複合体、請求項30に記載の核酸分子、請求項31に記載のベクター、請求項32に記載の組成物、または請求項33に記載の細胞。
- 必要のある被験者に、有効量の請求項1~28のいずれか1項に記載の融合タンパク質、請求項29に記載の免疫複合体、請求項30に記載の核酸分子、請求項31に記載のベクター、請求項32に記載の組成物、または請求項33に記載の細胞を投与することを含む、
PD-L1タンパク質とPD-1の相互作用を遮断する方法。 - 必要のある被験者に、有効量の請求項1~28のいずれか1項に記載の融合タンパク質、請求項29に記載の免疫複合体、請求項30に記載の核酸分子、請求項31に記載のベクター、請求項32に記載の組成物、または請求項33に記載の細胞を投与することを含む、
CD47タンパク質とSIRPαの相互作用を遮断する方法。 - 必要のある被験者に、有効量の請求項1~28のいずれか1項に記載の融合タンパク質、請求項29に記載の免疫複合体、請求項30に記載の核酸分子、請求項31に記載のベクター、請求項32に記載の組成物、または請求項33に記載の細胞を投与することを含む、
腫瘍または腫瘍細胞の成長および/または増殖を阻害する方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910260447.5 | 2019-04-02 | ||
CN201910260447.5A CN111763261B (zh) | 2019-04-02 | 2019-04-02 | 一种融合蛋白及其用途 |
PCT/CN2020/082861 WO2020200256A1 (zh) | 2019-04-02 | 2020-04-01 | 一种融合蛋白及其用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2022527705A true JP2022527705A (ja) | 2022-06-03 |
Family
ID=72664537
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021556959A Pending JP2022527705A (ja) | 2019-04-02 | 2020-04-01 | 融合タンパク質およびその使用 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220251154A1 (ja) |
EP (1) | EP3950720A4 (ja) |
JP (1) | JP2022527705A (ja) |
KR (1) | KR20210146916A (ja) |
CN (2) | CN111763261B (ja) |
AU (1) | AU2020250613A1 (ja) |
BR (1) | BR112021019570A2 (ja) |
CA (1) | CA3131075A1 (ja) |
SG (1) | SG11202110400QA (ja) |
WO (1) | WO2020200256A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4296284A1 (en) * | 2021-02-19 | 2023-12-27 | SHAPERON Inc. | Bispecific single domain antibody to pd-l1 and cd47 and use thereof |
CN113773401B (zh) * | 2021-09-15 | 2023-06-20 | 宜明昂科生物医药技术(上海)股份有限公司 | 靶向cd47和pd-l1的重组融合蛋白及其制备和用途 |
TW202330631A (zh) * | 2021-11-01 | 2023-08-01 | 大陸商江蘇先聲藥業有限公司 | SIRPa突變體及其應用 |
CN116178561A (zh) * | 2021-11-26 | 2023-05-30 | 杭州尚健生物技术有限公司 | 包含SIRPα突变体的融合蛋白 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
GB8822228D0 (en) | 1988-09-21 | 1988-10-26 | Southern E M | Support-bound oligonucleotides |
EP2167531B1 (en) * | 2007-05-25 | 2012-03-21 | Novartis AG | Streptococcus pneumoniae pilus antigens |
MX2013013054A (es) * | 2011-05-12 | 2014-02-20 | Genentech Inc | Metodo de monitoreo de lc-ms/ms de reaccion multiple para detectar anticuerpos terapeuticos en muestras de animales utilizando peptidos de firma de estructura. |
TWI759810B (zh) * | 2014-08-08 | 2022-04-01 | 美商Alx腫瘤技術股份有限公司 | 信號調節蛋白α(signal-regulatory proteinα, SIRP-α)變體構築物及其用途 |
US10087257B2 (en) * | 2014-08-08 | 2018-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | SIRP alpha-antibody fusion proteins |
ES2751915T5 (es) * | 2014-08-15 | 2022-12-23 | Merck Patent Gmbh | Proteínas de fusión de inmunoglobulina con SIRP alfa |
CN108350048B (zh) * | 2015-08-07 | 2024-02-09 | Alx肿瘤生物技术公司 | 具有SIRP-α结构域或其变体的构建体 |
AU2016306597A1 (en) * | 2015-08-07 | 2018-02-22 | Pieris Pharmaceuticals Gmbh | Novel fusion polypeptide specific for LAG-3 and PD-1 |
CN107459578B (zh) * | 2016-05-31 | 2021-11-26 | 泰州迈博太科药业有限公司 | 一种靶向cd47与pd-l1的双功能融合蛋白 |
CN106967172B (zh) * | 2016-08-23 | 2019-01-08 | 康方药业有限公司 | 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途 |
SG10201912879YA (en) * | 2016-12-09 | 2020-02-27 | Alector Llc | Anti-sirp-alpha antibodies and methods of use thereof |
US11518810B2 (en) * | 2017-05-08 | 2022-12-06 | Shanghai Jmt-Bio Technology Co., Ltd. | Bispecific recombinant protein and use thereof |
CN109517054B (zh) * | 2018-12-04 | 2022-04-08 | 江苏东抗生物医药科技有限公司 | SIRPα变体或其融合蛋白及其应用 |
CN109535263B (zh) * | 2018-12-04 | 2022-06-17 | 江苏东抗生物医药科技有限公司 | SIRPα突变体及其融合蛋白 |
-
2019
- 2019-04-02 CN CN201910260447.5A patent/CN111763261B/zh active Active
-
2020
- 2020-04-01 WO PCT/CN2020/082861 patent/WO2020200256A1/zh unknown
- 2020-04-01 SG SG11202110400QA patent/SG11202110400QA/en unknown
- 2020-04-01 EP EP20782966.4A patent/EP3950720A4/en active Pending
- 2020-04-01 BR BR112021019570A patent/BR112021019570A2/pt unknown
- 2020-04-01 KR KR1020217030645A patent/KR20210146916A/ko not_active Application Discontinuation
- 2020-04-01 CA CA3131075A patent/CA3131075A1/en active Pending
- 2020-04-01 CN CN202080023723.7A patent/CN113631582A/zh active Pending
- 2020-04-01 AU AU2020250613A patent/AU2020250613A1/en not_active Abandoned
- 2020-04-01 JP JP2021556959A patent/JP2022527705A/ja active Pending
- 2020-04-01 US US17/599,733 patent/US20220251154A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3131075A1 (en) | 2020-10-08 |
EP3950720A4 (en) | 2023-04-12 |
AU2020250613A1 (en) | 2021-11-11 |
WO2020200256A1 (zh) | 2020-10-08 |
KR20210146916A (ko) | 2021-12-06 |
CN111763261A (zh) | 2020-10-13 |
SG11202110400QA (en) | 2021-10-28 |
US20220251154A1 (en) | 2022-08-11 |
EP3950720A1 (en) | 2022-02-09 |
CN113631582A (zh) | 2021-11-09 |
CN111763261B (zh) | 2022-08-09 |
BR112021019570A2 (pt) | 2021-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6783886B2 (ja) | 抗ctla4モノクローナル抗体またはその抗原結合断片、医薬組成物および使用 | |
KR102503084B1 (ko) | 항-ctla4 및 항-pd-1 이작용성 항체, 이의 약제학적 조성물 및 이의 용도 | |
KR102469286B1 (ko) | 항-pd1 단일클론 항체, 이의 약제학적 조성물 및 이의 용도 | |
JP6432121B2 (ja) | Pdl−1抗体、その医薬組成物及びその使用 | |
WO2017071625A1 (zh) | 一种抗pd-1单克隆抗体、其药物组合物及其用途 | |
WO2020043184A1 (zh) | 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途 | |
JP2022527705A (ja) | 融合タンパク質およびその使用 | |
KR20210018336A (ko) | 항인터류킨-17a 항체, 그의 약학 조성물 및 용도 | |
JP2022513008A (ja) | 融合タンパク質およびその使用 | |
WO2023093831A1 (zh) | 包含SIRPα突变体的融合蛋白 | |
JP2023542283A (ja) | 抗pvrigタンパク質抗体又は抗体断片及びその使用 | |
CN115521378B (zh) | Pd-l1抗体及其用途 | |
TW202144412A (zh) | 一種融合蛋白及其用途 | |
WO2024051223A1 (zh) | 药物组合及用途 | |
WO2023241629A1 (zh) | 抗cldn18.2抗体、其药物组合物及用途 | |
CN115724969A (zh) | Lag-3结合分子及其应用 | |
CN115215936A (zh) | Csf1r抗原结合蛋白 | |
CN116102655A (zh) | 靶向pd-l1/pd-1的抗体及其应用 | |
EA042365B1 (ru) | Бифункциональное антитело против ctla4 и против pd-1, его фармацевтическая композиция и их применение |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20210922 Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211008 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220307 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230221 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240305 |